false
OasisLMS
Login
Catalog
Kidney Week 2026 Early Program On-Demand - Onconep ...
Thrombotic Microangiopathy in Patients with Cancer ...
Thrombotic Microangiopathy in Patients with Cancer: Decoding the Role of Complement Regulation and Inhibition
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
The talk examines how complement contributes to cancer-associated thrombotic microangiopathy (TMA) and when complement-blocking treatment may help. TMA is a pattern of injury with many possible causes, so the speaker recommends replacing the outdated “primary” versus “secondary” labels with descriptions based on the suspected trigger and evolving evidence.<br /><br />Complement may be a disease driver, an amplifier of endothelial injury, or a bystander. In cancer, it most often appears to amplify injury caused by drugs, transplantation, or other insults. By contrast, monoclonal protein–related complement dysregulation may drive disease and call for clone-directed treatment. When the cancer itself causes microangiopathy, treating the cancer—not complement—is central.<br /><br />Clinicians should first urgently exclude TTP and DIC, then assess the trigger, disease severity, and kidney response. Complement inhibition may be considered when TMA is severe or persists despite removing the suspected trigger, but evidence varies by setting and is often based on small or uncontrolled studies. Blood-count improvement does not necessarily mean kidney recovery. The speaker emphasizes individualized treatment, careful planning for treatment duration and infection prevention, and the need for validated biomarkers and stronger clinical trials.
Asset Caption
Anuja Java, MD
Meta Tag
Speaker
Anuja Java
Keywords
cancer-associated thrombotic microangiopathy
complement inhibition
endothelial injury
monoclonal protein dysregulation
treatment-triggered TMA
kidney response
thrombotic microangiopathy diagnosis
×
Please select your language
1
English